JP2013538198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538198A5 JP2013538198A5 JP2013523638A JP2013523638A JP2013538198A5 JP 2013538198 A5 JP2013538198 A5 JP 2013538198A5 JP 2013523638 A JP2013523638 A JP 2013523638A JP 2013523638 A JP2013523638 A JP 2013523638A JP 2013538198 A5 JP2013538198 A5 JP 2013538198A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ethyl
- methyl
- benzyl
- sulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 37
- 239000001257 hydrogen Substances 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 5
- -1 C 1 -C 6 -alkoxy Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 4
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- YUEYKOAMVDQBAX-UHFFFAOYSA-N n-[2-[3-(3-benzylazetidin-3-yl)phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C2(CC=3C=CC=CC=3)CNC2)=C1 YUEYKOAMVDQBAX-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- UXIOOCXFWZVFHA-UHFFFAOYSA-N 1-cyclopropyl-n-[[3-(1-morpholin-4-yl-3-phenylpropan-2-yl)phenyl]methyl]methanesulfonamide Chemical compound C=1C=CC(C(CN2CCOCC2)CC=2C=CC=CC=2)=CC=1CNS(=O)(=O)CC1CC1 UXIOOCXFWZVFHA-UHFFFAOYSA-N 0.000 claims 1
- ADWQNYPZFCWFJT-UHFFFAOYSA-N 1-methyl-n-[2-[3-(1-phenyl-3-pyrrolidin-1-ylpropan-2-yl)phenoxy]ethyl]imidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C(CN2CCCC2)CC=2C=CC=CC=2)=C1 ADWQNYPZFCWFJT-UHFFFAOYSA-N 0.000 claims 1
- RGZQWLFZGIRJMF-UHFFFAOYSA-N 1-methyl-n-[[3-(1-morpholin-4-yl-1-oxo-3-phenylpropan-2-yl)phenyl]methyl]imidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCC=2C=C(C=CC=2)C(CC=2C=CC=CC=2)C(=O)N2CCOCC2)=C1 RGZQWLFZGIRJMF-UHFFFAOYSA-N 0.000 claims 1
- DMKZOFYTZBUHGZ-UHFFFAOYSA-N 1-methyl-n-[[3-(1-morpholin-4-yl-3-phenylpropan-2-yl)phenyl]methyl]imidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCC=2C=C(C=CC=2)C(CN2CCOCC2)CC=2C=CC=CC=2)=C1 DMKZOFYTZBUHGZ-UHFFFAOYSA-N 0.000 claims 1
- FMXDGIFSBYAIOK-UHFFFAOYSA-N 1-methyl-n-[[3-(1-morpholin-4-yl-3-phenylpropan-2-yl)phenyl]methyl]pyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCC1=CC=CC(C(CN2CCOCC2)CC=2C=CC=CC=2)=C1 FMXDGIFSBYAIOK-UHFFFAOYSA-N 0.000 claims 1
- KSZCAGWHZCZJLZ-UHFFFAOYSA-N 1-methylimidazole-4-sulfonic acid Chemical compound CN1C=NC(S(O)(=O)=O)=C1 KSZCAGWHZCZJLZ-UHFFFAOYSA-N 0.000 claims 1
- WHYASBKVZHKQTN-UHFFFAOYSA-N 1-methylpyrazole-4-sulfonic acid Chemical compound CN1C=C(S(O)(=O)=O)C=N1 WHYASBKVZHKQTN-UHFFFAOYSA-N 0.000 claims 1
- JLMQINUOMQKYQB-UHFFFAOYSA-N 2-[3-[(cyclopropylmethylsulfonylamino)methyl]phenyl]-3-phenylpropanamide Chemical compound C=1C=CC(CNS(=O)(=O)CC2CC2)=CC=1C(C(=O)N)CC1=CC=CC=C1 JLMQINUOMQKYQB-UHFFFAOYSA-N 0.000 claims 1
- FZCRCUPHHLNAON-UHFFFAOYSA-N 2-[3-[[(1-methylimidazol-4-yl)sulfonylamino]methyl]phenyl]-3-phenylpropanamide Chemical compound CN1C=NC(S(=O)(=O)NCC=2C=C(C=CC=2)C(CC=2C=CC=CC=2)C(N)=O)=C1 FZCRCUPHHLNAON-UHFFFAOYSA-N 0.000 claims 1
- HJBAFMRHRSTANB-UHFFFAOYSA-N 2-[3-[[(1-methylpyrazol-4-yl)sulfonylamino]methyl]phenyl]-3-phenylpropanamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCC1=CC=CC(C(CC=2C=CC=CC=2)C(N)=O)=C1 HJBAFMRHRSTANB-UHFFFAOYSA-N 0.000 claims 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- PQSAQCVJELMITK-UHFFFAOYSA-N ethyl 3-benzyl-3-[3-[2-(cyclopropylmethylsulfonylamino)ethoxy]phenyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CC1(C=1C=C(OCCNS(=O)(=O)CC2CC2)C=CC=1)CC1=CC=CC=C1 PQSAQCVJELMITK-UHFFFAOYSA-N 0.000 claims 1
- OYTBMOZGOUDYTI-UHFFFAOYSA-N ethyl 3-benzyl-3-[3-[2-[(1-methylimidazol-4-yl)sulfonylamino]ethoxy]phenyl]azetidine-1-carboxylate Chemical compound C1N(C(=O)OCC)CC1(C=1C=C(OCCNS(=O)(=O)C=2N=CN(C)C=2)C=CC=1)CC1=CC=CC=C1 OYTBMOZGOUDYTI-UHFFFAOYSA-N 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- PKUCOECXEYLXBZ-UHFFFAOYSA-N n-[2-[3-(1-amino-3-phenylpropan-2-yl)-4-fluorophenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C(F)=CC=2)C(CN)CC=2C=CC=CC=2)=C1 PKUCOECXEYLXBZ-UHFFFAOYSA-N 0.000 claims 1
- VWYDDIGQGBFYCZ-UHFFFAOYSA-N n-[2-[3-(1-amino-3-phenylpropan-2-yl)phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C(CN)CC=2C=CC=CC=2)=C1 VWYDDIGQGBFYCZ-UHFFFAOYSA-N 0.000 claims 1
- MZBQASAPYIATSP-UHFFFAOYSA-N n-[2-[3-(1-amino-3-phenylpropan-2-yl)phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C(CN)CC=2C=CC=CC=2)=C1 MZBQASAPYIATSP-UHFFFAOYSA-N 0.000 claims 1
- DOQKGALNCBHDBJ-UHFFFAOYSA-N n-[2-[3-(3-benzyl-1-methylpiperidin-3-yl)phenoxy]ethyl]-1-cyclopropylmethanesulfonamide Chemical compound C1N(C)CCCC1(C=1C=C(OCCNS(=O)(=O)CC2CC2)C=CC=1)CC1=CC=CC=C1 DOQKGALNCBHDBJ-UHFFFAOYSA-N 0.000 claims 1
- REUMXPBOWOBHQD-UHFFFAOYSA-N n-[2-[3-(3-benzyl-1-methylpiperidin-3-yl)phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C1N(C)CCCC1(C=1C=C(OCCNS(=O)(=O)C=2N=CN(C)C=2)C=CC=1)CC1=CC=CC=C1 REUMXPBOWOBHQD-UHFFFAOYSA-N 0.000 claims 1
- DSXNXHSTAJFSMS-UHFFFAOYSA-N n-[2-[3-(3-benzyl-1-methylpiperidin-3-yl)phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1N(C)CCCC1(C=1C=C(OCCNS(=O)(=O)C2=CN(C)N=C2)C=CC=1)CC1=CC=CC=C1 DSXNXHSTAJFSMS-UHFFFAOYSA-N 0.000 claims 1
- MCGLETVIBZJYLF-UHFFFAOYSA-N n-[2-[3-(3-benzyl-1-methylpyrrolidin-3-yl)phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C1N(C)CCC1(C=1C=C(OCCNS(=O)(=O)C=2N=CN(C)C=2)C=CC=1)CC1=CC=CC=C1 MCGLETVIBZJYLF-UHFFFAOYSA-N 0.000 claims 1
- PKUNQFTZTCBZGM-UHFFFAOYSA-N n-[2-[3-(3-benzyl-1-methylpyrrolidin-3-yl)phenoxy]ethyl]-n,1-dimethylimidazole-4-sulfonamide Chemical compound C=1N(C)C=NC=1S(=O)(=O)N(C)CCOC(C=1)=CC=CC=1C1(CC=2C=CC=CC=2)CCN(C)C1 PKUNQFTZTCBZGM-UHFFFAOYSA-N 0.000 claims 1
- RJMXPCSRWXTANQ-UHFFFAOYSA-N n-[2-[3-(3-benzyl-1-propan-2-ylpyrrolidin-3-yl)phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C1N(C(C)C)CCC1(C=1C=C(OCCNS(=O)(=O)C=2N=CN(C)C=2)C=CC=1)CC1=CC=CC=C1 RJMXPCSRWXTANQ-UHFFFAOYSA-N 0.000 claims 1
- OSKPYFWBFJONLR-UHFFFAOYSA-N n-[2-[3-(3-benzyl-5-oxopyrrolidin-3-yl)phenoxy]ethyl]-1-cyclopropylmethanesulfonamide Chemical compound C1NC(=O)CC1(C=1C=C(OCCNS(=O)(=O)CC2CC2)C=CC=1)CC1=CC=CC=C1 OSKPYFWBFJONLR-UHFFFAOYSA-N 0.000 claims 1
- ZPYOWFUKZRMFLZ-UHFFFAOYSA-N n-[2-[3-(3-benzyl-5-oxopyrrolidin-3-yl)phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CC(=O)NC2)=C1 ZPYOWFUKZRMFLZ-UHFFFAOYSA-N 0.000 claims 1
- MQFRFPIYIFJECT-UHFFFAOYSA-N n-[2-[3-(3-benzyl-5-oxopyrrolidin-3-yl)phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C2(CC=3C=CC=CC=3)CC(=O)NC2)=C1 MQFRFPIYIFJECT-UHFFFAOYSA-N 0.000 claims 1
- UBLSYMJIAYDMPF-UHFFFAOYSA-N n-[2-[3-(3-benzylazetidin-3-yl)phenoxy]ethyl]-1-cyclopropylmethanesulfonamide Chemical compound C=1C=CC(C2(CC=3C=CC=CC=3)CNC2)=CC=1OCCNS(=O)(=O)CC1CC1 UBLSYMJIAYDMPF-UHFFFAOYSA-N 0.000 claims 1
- QGSIOHCMIXWVQS-UHFFFAOYSA-N n-[2-[3-(3-benzylazetidin-3-yl)phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CNC2)=C1 QGSIOHCMIXWVQS-UHFFFAOYSA-N 0.000 claims 1
- KOMIOKKXRGKQFZ-UHFFFAOYSA-N n-[2-[3-(3-benzylpyrrolidin-3-yl)phenoxy]ethyl]-1-cyclopropylmethanesulfonamide Chemical compound C=1C=CC(C2(CC=3C=CC=CC=3)CNCC2)=CC=1OCCNS(=O)(=O)CC1CC1 KOMIOKKXRGKQFZ-UHFFFAOYSA-N 0.000 claims 1
- SMMSWRPABQHXRV-UHFFFAOYSA-N n-[2-[3-(3-benzylpyrrolidin-3-yl)phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CNCC2)=C1 SMMSWRPABQHXRV-UHFFFAOYSA-N 0.000 claims 1
- CFTHJDDWWCKSQB-UHFFFAOYSA-N n-[2-[3-(3-benzylpyrrolidin-3-yl)phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C2(CC=3C=CC=CC=3)CNCC2)=C1 CFTHJDDWWCKSQB-UHFFFAOYSA-N 0.000 claims 1
- MWDMPXOTEHTCSL-UHFFFAOYSA-N n-[2-[3-[(benzylamino)-[1-(4-chlorophenyl)cyclobutyl]methyl]phenoxy]ethyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NCCOC1=CC=CC(C(NCC=2C=CC=CC=2)C2(CCC2)C=2C=CC(Cl)=CC=2)=C1 MWDMPXOTEHTCSL-UHFFFAOYSA-N 0.000 claims 1
- TYSSRHFFJQXYGK-UHFFFAOYSA-N n-[2-[3-[1-(azetidin-1-yl)-3-phenylpropan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C(CN2CCC2)CC=2C=CC=CC=2)=C1 TYSSRHFFJQXYGK-UHFFFAOYSA-N 0.000 claims 1
- KQHLMNNUVYBWTO-UHFFFAOYSA-N n-[2-[3-[1-(dimethylamino)-3-[3-(trifluoromethyl)phenyl]propan-2-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C=1C=CC(OCCNS(=O)(=O)C=2N=CN(C)C=2)=CC=1C(CN(C)C)CC1=CC=CC(C(F)(F)F)=C1 KQHLMNNUVYBWTO-UHFFFAOYSA-N 0.000 claims 1
- IAGZMVOWQPSWDX-UHFFFAOYSA-N n-[2-[3-[1-(dimethylamino)-3-[3-(trifluoromethyl)phenyl]propan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C=1C=CC(OCCNS(=O)(=O)C2=CN(C)N=C2)=CC=1C(CN(C)C)CC1=CC=CC(C(F)(F)F)=C1 IAGZMVOWQPSWDX-UHFFFAOYSA-N 0.000 claims 1
- HQMRYTKVVGMYIS-UHFFFAOYSA-N n-[2-[3-[1-(dimethylamino)-3-phenylpropan-2-yl]-4-fluorophenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C=1C(OCCNS(=O)(=O)C=2N=CN(C)C=2)=CC=C(F)C=1C(CN(C)C)CC1=CC=CC=C1 HQMRYTKVVGMYIS-UHFFFAOYSA-N 0.000 claims 1
- BEUJACZOHGUWES-UHFFFAOYSA-N n-[2-[3-[1-(dimethylamino)-3-phenylpropan-2-yl]-4-fluorophenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C=1C(OCCNS(=O)(=O)C2=CN(C)N=C2)=CC=C(F)C=1C(CN(C)C)CC1=CC=CC=C1 BEUJACZOHGUWES-UHFFFAOYSA-N 0.000 claims 1
- JVJZPQXPPCKFEZ-UHFFFAOYSA-N n-[2-[3-[1-(dimethylamino)-3-phenylpropan-2-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C=1C=CC(OCCNS(=O)(=O)C=2N=CN(C)C=2)=CC=1C(CN(C)C)CC1=CC=CC=C1 JVJZPQXPPCKFEZ-UHFFFAOYSA-N 0.000 claims 1
- JRJOEONTFKCOPP-UHFFFAOYSA-N n-[2-[3-[1-(dimethylamino)-3-phenylpropan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C=1C=CC(OCCNS(=O)(=O)C2=CN(C)N=C2)=CC=1C(CN(C)C)CC1=CC=CC=C1 JRJOEONTFKCOPP-UHFFFAOYSA-N 0.000 claims 1
- OUJINOAVBIQSRB-UHFFFAOYSA-N n-[2-[3-[1-amino-3-(3,5-difluorophenyl)propan-2-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C(CN)CC=2C=C(F)C=C(F)C=2)=C1 OUJINOAVBIQSRB-UHFFFAOYSA-N 0.000 claims 1
- MTZHVAHBLJFAHL-UHFFFAOYSA-N n-[2-[3-[1-amino-3-(3,5-difluorophenyl)propan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C(CN)CC=2C=C(F)C=C(F)C=2)=C1 MTZHVAHBLJFAHL-UHFFFAOYSA-N 0.000 claims 1
- LMEZXEOCQVSTPY-UHFFFAOYSA-N n-[2-[3-[1-amino-3-(3-chlorophenyl)propan-2-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C(CN)CC=2C=C(Cl)C=CC=2)=C1 LMEZXEOCQVSTPY-UHFFFAOYSA-N 0.000 claims 1
- VGYSKYKJEAUUFY-UHFFFAOYSA-N n-[2-[3-[1-amino-3-(3-chlorophenyl)propan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C(CN)CC=2C=C(Cl)C=CC=2)=C1 VGYSKYKJEAUUFY-UHFFFAOYSA-N 0.000 claims 1
- QKQRCZOFDCTJEI-UHFFFAOYSA-N n-[2-[3-[1-amino-3-(4-chlorophenyl)propan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C(CN)CC=2C=CC(Cl)=CC=2)=C1 QKQRCZOFDCTJEI-UHFFFAOYSA-N 0.000 claims 1
- NSHUYSXZUJRBBM-UHFFFAOYSA-N n-[2-[3-[1-amino-3-[3-(trifluoromethyl)phenyl]propan-2-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C(CN)CC=2C=C(C=CC=2)C(F)(F)F)=C1 NSHUYSXZUJRBBM-UHFFFAOYSA-N 0.000 claims 1
- RCAWJWRNXYTGTP-UHFFFAOYSA-N n-[2-[3-[1-amino-3-[3-(trifluoromethyl)phenyl]propan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC=CC(C(CN)CC=2C=C(C=CC=2)C(F)(F)F)=C1 RCAWJWRNXYTGTP-UHFFFAOYSA-N 0.000 claims 1
- OBDPJNWADSEKSU-UHFFFAOYSA-N n-[2-[3-[3-benzyl-1-(2,2-difluoroacetyl)pyrrolidin-3-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CN(CC2)C(=O)C(F)F)=C1 OBDPJNWADSEKSU-UHFFFAOYSA-N 0.000 claims 1
- HGSLOXWYEMKWHX-UHFFFAOYSA-N n-[2-[3-[3-benzyl-1-(2,2-difluoroethyl)azetidin-3-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CN(CC(F)F)C2)=C1 HGSLOXWYEMKWHX-UHFFFAOYSA-N 0.000 claims 1
- DZYLUNISZUPZNH-UHFFFAOYSA-N n-[2-[3-[3-benzyl-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CN(CC(C)(C)C)CC2)=C1 DZYLUNISZUPZNH-UHFFFAOYSA-N 0.000 claims 1
- LCCOIUSPPDYVKE-UHFFFAOYSA-N n-[2-[3-[3-benzyl-1-(2-fluoroethyl)azetidin-3-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CN(CCF)C2)=C1 LCCOIUSPPDYVKE-UHFFFAOYSA-N 0.000 claims 1
- RIHPVPXINBTIQI-UHFFFAOYSA-N n-[2-[3-[3-benzyl-1-(2-fluoroethyl)pyrrolidin-3-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CN(CCF)CC2)=C1 RIHPVPXINBTIQI-UHFFFAOYSA-N 0.000 claims 1
- PSEPDAHDYDEDNC-UHFFFAOYSA-N n-[2-[3-[3-benzyl-1-(2-methoxyethyl)azetidin-3-yl]phenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C1N(CCOC)CC1(C=1C=C(OCCNS(=O)(=O)C=2N=CN(C)C=2)C=CC=1)CC1=CC=CC=C1 PSEPDAHDYDEDNC-UHFFFAOYSA-N 0.000 claims 1
- XAOTZCGJNCMQTI-UHFFFAOYSA-N n-[2-[4-chloro-3-[1-(dimethylamino)-3-phenylpropan-2-yl]phenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C=1C(OCCNS(=O)(=O)C2=CN(C)N=C2)=CC=C(Cl)C=1C(CN(C)C)CC1=CC=CC=C1 XAOTZCGJNCMQTI-UHFFFAOYSA-N 0.000 claims 1
- QQSQJTIMNPKWSG-UHFFFAOYSA-N n-[2-[5-(1-amino-3-phenylpropan-2-yl)-2-fluorophenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCCOC=2C(=CC=C(C=2)C(CN)CC=2C=CC=CC=2)F)=C1 QQSQJTIMNPKWSG-UHFFFAOYSA-N 0.000 claims 1
- MJBGPNPKELCMGC-UHFFFAOYSA-N n-[2-[5-(1-amino-3-phenylpropan-2-yl)-2-fluorophenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCCOC1=CC(C(CN)CC=2C=CC=CC=2)=CC=C1F MJBGPNPKELCMGC-UHFFFAOYSA-N 0.000 claims 1
- DRPPFVAIHWQKOO-UHFFFAOYSA-N n-[2-[5-(3-benzyl-1-methylazetidin-3-yl)-2-fluorophenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C1N(C)CC1(C=1C=C(OCCNS(=O)(=O)C=2N=CN(C)C=2)C(F)=CC=1)CC1=CC=CC=C1 DRPPFVAIHWQKOO-UHFFFAOYSA-N 0.000 claims 1
- ZLOGEPWQDUFPRX-UHFFFAOYSA-N n-[2-[5-(3-benzyl-1-methylazetidin-3-yl)-2-fluorophenoxy]ethyl]-n,1-dimethylimidazole-4-sulfonamide Chemical compound C=1N(C)C=NC=1S(=O)(=O)N(C)CCOC(C(=CC=1)F)=CC=1C1(CC=2C=CC=CC=2)CN(C)C1 ZLOGEPWQDUFPRX-UHFFFAOYSA-N 0.000 claims 1
- AKTCMKHHANHAPV-UHFFFAOYSA-N n-[2-[5-[1-(dimethylamino)-3-phenylpropan-2-yl]-2-fluorophenoxy]ethyl]-1-methylimidazole-4-sulfonamide Chemical compound C=1C=C(F)C(OCCNS(=O)(=O)C=2N=CN(C)C=2)=CC=1C(CN(C)C)CC1=CC=CC=C1 AKTCMKHHANHAPV-UHFFFAOYSA-N 0.000 claims 1
- IMGNZWFDWZCPBK-UHFFFAOYSA-N n-[2-[5-[1-(dimethylamino)-3-phenylpropan-2-yl]-2-fluorophenoxy]ethyl]-1-methylpyrazole-4-sulfonamide Chemical compound C=1C=C(F)C(OCCNS(=O)(=O)C2=CN(C)N=C2)=CC=1C(CN(C)C)CC1=CC=CC=C1 IMGNZWFDWZCPBK-UHFFFAOYSA-N 0.000 claims 1
- ZDRRHNXYLOAVPH-UHFFFAOYSA-N n-[[3-(1-amino-3-phenylpropan-2-yl)phenyl]methyl]-1-cyclopropylmethanesulfonamide Chemical compound C=1C=CC(CNS(=O)(=O)CC2CC2)=CC=1C(CN)CC1=CC=CC=C1 ZDRRHNXYLOAVPH-UHFFFAOYSA-N 0.000 claims 1
- BRSSHYRDXFAGBU-UHFFFAOYSA-N n-[[3-(1-amino-3-phenylpropan-2-yl)phenyl]methyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCC=2C=C(C=CC=2)C(CN)CC=2C=CC=CC=2)=C1 BRSSHYRDXFAGBU-UHFFFAOYSA-N 0.000 claims 1
- KGBATTRBSMKHMW-UHFFFAOYSA-N n-[[3-(1-amino-3-phenylpropan-2-yl)phenyl]methyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCC1=CC=CC(C(CN)CC=2C=CC=CC=2)=C1 KGBATTRBSMKHMW-UHFFFAOYSA-N 0.000 claims 1
- MXWWAZZLJCLTPJ-UHFFFAOYSA-N n-[[3-(3-benzyl-1-methylpyrrolidin-3-yl)phenyl]methyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1N(C)CCC1(C=1C=C(CNS(=O)(=O)C2=CN(C)N=C2)C=CC=1)CC1=CC=CC=C1 MXWWAZZLJCLTPJ-UHFFFAOYSA-N 0.000 claims 1
- URILZVILCGHFJP-UHFFFAOYSA-N n-[[3-(3-benzyl-5-oxopyrrolidin-3-yl)phenyl]methyl]-1-methylimidazole-4-sulfonamide Chemical compound CN1C=NC(S(=O)(=O)NCC=2C=C(C=CC=2)C2(CC=3C=CC=CC=3)CC(=O)NC2)=C1 URILZVILCGHFJP-UHFFFAOYSA-N 0.000 claims 1
- GJNGATNTYBDWQM-UHFFFAOYSA-N n-[[3-(3-benzyl-5-oxopyrrolidin-3-yl)phenyl]methyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCC1=CC=CC(C2(CC=3C=CC=CC=3)CC(=O)NC2)=C1 GJNGATNTYBDWQM-UHFFFAOYSA-N 0.000 claims 1
- LPVHWPGGFBBWCR-UHFFFAOYSA-N n-[[3-(3-benzylpyrrolidin-3-yl)phenyl]methyl]-1-cyclopropylmethanesulfonamide Chemical compound C=1C=CC(C2(CC=3C=CC=CC=3)CNCC2)=CC=1CNS(=O)(=O)CC1CC1 LPVHWPGGFBBWCR-UHFFFAOYSA-N 0.000 claims 1
- FSONNASPZTXNNS-UHFFFAOYSA-N n-[[3-(3-benzylpyrrolidin-3-yl)phenyl]methyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCC1=CC=CC(C2(CC=3C=CC=CC=3)CNCC2)=C1 FSONNASPZTXNNS-UHFFFAOYSA-N 0.000 claims 1
- SPVOBSRIRDTEGQ-UHFFFAOYSA-N n-[[3-[1-(azetidin-1-yl)-3-phenylpropan-2-yl]phenyl]methyl]-1-methylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)NCC1=CC=CC(C(CN2CCC2)CC=2C=CC=CC=2)=C1 SPVOBSRIRDTEGQ-UHFFFAOYSA-N 0.000 claims 1
- XFRGCVFDVSCQRH-UHFFFAOYSA-N n-[[3-[1-(dimethylamino)-3-phenylpropan-2-yl]phenyl]methyl]-1-methylimidazole-4-sulfonamide Chemical compound C=1C=CC(CNS(=O)(=O)C=2N=CN(C)C=2)=CC=1C(CN(C)C)CC1=CC=CC=C1 XFRGCVFDVSCQRH-UHFFFAOYSA-N 0.000 claims 1
- QGGAKKSZEJBICI-UHFFFAOYSA-N n-[[3-[1-(dimethylamino)-3-phenylpropan-2-yl]phenyl]methyl]-1-methylpyrazole-4-sulfonamide Chemical compound C=1C=CC(CNS(=O)(=O)C2=CN(C)N=C2)=CC=1C(CN(C)C)CC1=CC=CC=C1 QGGAKKSZEJBICI-UHFFFAOYSA-N 0.000 claims 1
- PGAACESYQNEENM-UHFFFAOYSA-N n-[[3-[2-amino-1-[1-(4-chlorophenyl)cyclobutyl]ethyl]phenyl]methyl]-3-fluoro-n-methylpropane-1-sulfonamide Chemical compound FCCCS(=O)(=O)N(C)CC1=CC=CC(C(CN)C2(CCC2)C=2C=CC(Cl)=CC=2)=C1 PGAACESYQNEENM-UHFFFAOYSA-N 0.000 claims 1
- GXPJAZBKQXPNOX-UHFFFAOYSA-N n-[[3-[2-amino-1-[1-(4-chlorophenyl)cyclobutyl]ethyl]phenyl]methyl]-n,1-dimethylimidazole-4-sulfonamide Chemical compound C=1N(C)C=NC=1S(=O)(=O)N(C)CC(C=1)=CC=CC=1C(CN)C1(C=2C=CC(Cl)=CC=2)CCC1 GXPJAZBKQXPNOX-UHFFFAOYSA-N 0.000 claims 1
- XBVOZHLSEUNVSM-UHFFFAOYSA-N n-[[3-[2-amino-1-[1-(4-chlorophenyl)cyclobutyl]ethyl]phenyl]methyl]-n,1-dimethylpyrazole-4-sulfonamide Chemical compound C1=NN(C)C=C1S(=O)(=O)N(C)CC(C=1)=CC=CC=1C(CN)C1(C=2C=CC(Cl)=CC=2)CCC1 XBVOZHLSEUNVSM-UHFFFAOYSA-N 0.000 claims 1
- GTQCWMOGRXRAJI-UHFFFAOYSA-N n-[[3-[2-amino-1-[1-(4-chlorophenyl)cyclobutyl]ethyl]phenyl]methyl]-n-methylpropane-1-sulfonamide Chemical compound CCCS(=O)(=O)N(C)CC1=CC=CC(C(CN)C2(CCC2)C=2C=CC(Cl)=CC=2)=C1 GTQCWMOGRXRAJI-UHFFFAOYSA-N 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- LRTPEYUVINTMGW-UHFFFAOYSA-N tert-butyl n-[2-[1-(4-chlorophenyl)cyclobutyl]-2-[3-[[methyl(propylsulfonyl)amino]methyl]phenyl]ethyl]carbamate Chemical compound CCCS(=O)(=O)N(C)CC1=CC=CC(C(CNC(=O)OC(C)(C)C)C2(CCC2)C=2C=CC(Cl)=CC=2)=C1 LRTPEYUVINTMGW-UHFFFAOYSA-N 0.000 claims 1
- QHKGGFXROLLYIK-UHFFFAOYSA-N tert-butyl n-[2-[1-(4-chlorophenyl)cyclobutyl]-2-[3-[[methyl-(1-methylpyrazol-4-yl)sulfonylamino]methyl]phenyl]ethyl]carbamate Chemical compound C1=NN(C)C=C1S(=O)(=O)N(C)CC(C=1)=CC=CC=1C(CNC(=O)OC(C)(C)C)C1(C=2C=CC(Cl)=CC=2)CCC1 QHKGGFXROLLYIK-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37352610P | 2010-08-13 | 2010-08-13 | |
| US61/373,526 | 2010-08-13 | ||
| PCT/EP2011/063971 WO2012020130A1 (en) | 2010-08-13 | 2011-08-12 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538198A JP2013538198A (ja) | 2013-10-10 |
| JP2013538198A5 true JP2013538198A5 (enExample) | 2014-09-25 |
Family
ID=44510967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523638A Pending JP2013538198A (ja) | 2010-08-13 | 2011-08-12 | フェナルキルアミン誘導体、それを含有する医薬組成物及び治療におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8877794B2 (enExample) |
| EP (1) | EP2603487A1 (enExample) |
| JP (1) | JP2013538198A (enExample) |
| CN (1) | CN103237788A (enExample) |
| CA (1) | CA2806643A1 (enExample) |
| MX (1) | MX2013001790A (enExample) |
| TW (1) | TW201211031A (enExample) |
| WO (1) | WO2012020130A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2527328A1 (en) | 2008-04-01 | 2012-11-28 | Abbott GmbH & Co. KG | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN103889968A (zh) | 2011-08-05 | 2014-06-25 | 艾伯维德国有限责任两合公司 | 氨基苯并二氢吡喃、氨基苯并二氢噻喃及氨基-1,2,3,4-四氢喹啉衍生物，包含这些化合物的药用组合物，及其在治疗中的用途 |
| MX2014006004A (es) | 2011-11-18 | 2015-04-16 | Abbvie Deutschland | Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CA2900888A1 (en) * | 2013-03-15 | 2014-09-18 | AbbVie Deutschland GmbH & Co. KG | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| AU2014336154A1 (en) | 2013-10-17 | 2016-04-28 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| JP2016537323A (ja) | 2013-10-17 | 2016-12-01 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン誘導体、アミノチオクロマン誘導体およびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用 |
| US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2019059244A1 (ja) | 2017-09-21 | 2019-03-28 | 日本農薬株式会社 | シクロプロピルピリジル基を有するベンゾイミダゾール化合物又はその塩類、及びそれらの化合物を含有する農園芸用殺虫剤並びにその使用方法 |
| AR130467A1 (es) * | 2022-09-12 | 2024-12-11 | Gilgamesh Pharmaceuticals Inc | Fenalquilaminas y métodos para fabricar y usar las mismas |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867391A (en) | 1973-08-09 | 1975-02-18 | Pfizer | Cyclic n-substituted derivatives of 1,4-benzene disulphonamide |
| SE8004002L (sv) | 1980-05-29 | 1981-11-30 | Arvidsson Folke Lars Erik | Terapeutiskt anvendbara tetralinderivat |
| EP0091241B1 (en) | 1982-04-02 | 1988-12-28 | Takeda Chemical Industries, Ltd. | Condensed pyrrolinone derivatives, and their production |
| US4789678A (en) | 1986-08-25 | 1988-12-06 | Hoechst-Roussel Pharmaceuticals, Inc. | Memory enhancing α-alkyl-4-amino-3-quinolinemethanols and 1-(4-aralkylamino-3-quinolinyl)alkanones and related compounds |
| US4927838A (en) | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
| ZA885824B (en) | 1987-08-14 | 1989-04-26 | Merrell Dow Pharma | Novel antidepressants |
| US5300523A (en) | 1988-07-28 | 1994-04-05 | Bayer Aktiengesellschaft | Substituted aminomethyltetralins and their heterocyclic analogues |
| US5545755A (en) | 1989-05-31 | 1996-08-13 | The Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
| WO1992006967A1 (en) | 1990-10-12 | 1992-04-30 | The Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
| CA2051399C (en) | 1989-05-31 | 2003-12-30 | Chiu-Hong Lin | Therapeutically useful 2-aminotetralin derivatives |
| US5071875A (en) | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
| CA2106197A1 (en) | 1991-04-26 | 1992-10-27 | Montford F. Piercey | Method of treating/preventing substance abuse |
| JPH05213884A (ja) | 1991-06-14 | 1993-08-24 | Upjohn Co:The | 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤 |
| GB9127306D0 (en) | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| CA2619901A1 (en) * | 1996-05-31 | 1997-12-04 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
| DE19740785A1 (de) * | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
| WO1998049158A1 (en) * | 1997-04-30 | 1998-11-05 | Warner-Lambert Company | Peripherally selective kappa opioid agonists |
| US6057357A (en) * | 1997-04-30 | 2000-05-02 | Warner-Lambert Company | Peripherally selective kappa opioid agonists |
| WO1998056757A1 (fr) | 1997-06-11 | 1998-12-17 | Sankyo Company, Limited | Derives de benzylamine |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| TW555757B (en) | 1998-07-31 | 2003-10-01 | Akzo Nobel Nv | Aminomethylcarboxylic acid derivatives |
| NZ510988A (en) | 1998-10-07 | 2005-01-28 | Ortho Mcneil Pharm Inc | N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor |
| EP1557168B1 (en) | 1999-07-26 | 2011-11-16 | Msd K.K. | Biarylurea Derivatives |
| ES2250170T3 (es) | 1999-07-28 | 2006-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Derivados de aminas y de amidas utilizados como ligando para el receptor y5 del neuropeptido y, util en el tratamiento de la obesidad y otros trantornos. |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6426364B1 (en) | 1999-11-01 | 2002-07-30 | Nps Allelix Corp. | Diaryl-enynes |
| JP2003518101A (ja) | 1999-12-21 | 2003-06-03 | アイカゲン インコーポレイテッド | カリウムチャネル阻害剤 |
| ATE398611T1 (de) * | 2000-05-08 | 2008-07-15 | Hoffmann La Roche | Para-amin substituierte phenylamid glukokinase activatoren |
| JP4850332B2 (ja) | 2000-10-18 | 2012-01-11 | 東京エレクトロン株式会社 | デュアルダマシン構造のエッチング方法 |
| IL157093A0 (en) | 2001-03-27 | 2004-02-08 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| AU2756602A (en) | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
| US6831193B2 (en) | 2001-05-18 | 2004-12-14 | Abbott Laboratories | Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors |
| EP1284257B1 (en) | 2001-08-16 | 2005-10-05 | Pfizer Products Inc. | Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter |
| DE10149370A1 (de) | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
| PT1446387E (pt) | 2001-11-21 | 2009-12-21 | Pharmacia & Upjohn Co Llc | Derivados de aril-1,4-pirazina substituídos |
| DE60219521T2 (de) | 2001-12-20 | 2007-08-16 | H. Lundbeck A/S | Aryloxyphenyl und arylsulfanylphenylderivate |
| GB0130696D0 (en) | 2001-12-21 | 2002-02-06 | Smithkline Beecham Plc | Chemical Compounds |
| JP4694129B2 (ja) | 2002-02-12 | 2011-06-08 | ナームローゼ・フエンノートチヤツプ・オルガノン | 中枢神経系疾患の治療において有用な１−アリールスルホニル−３−置換インドール及びインドリン誘導体 |
| DE10210779A1 (de) | 2002-03-12 | 2003-10-09 | Merck Patent Gmbh | Cyclische Amide |
| DE10217006A1 (de) | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
| FR2838739B1 (fr) | 2002-04-19 | 2004-05-28 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique |
| WO2003097586A1 (en) | 2002-05-17 | 2003-11-27 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| FR2842804B1 (fr) | 2002-07-29 | 2004-09-03 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
| FR2842805A1 (fr) | 2002-07-29 | 2004-01-30 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide,leur preparation et leur application et therapeutique |
| US20040152741A1 (en) | 2002-09-09 | 2004-08-05 | Nps Allelix Corporation | Arylglycine derivatives and their use as glycine transport inhibitors |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| US7084154B2 (en) | 2003-02-11 | 2006-08-01 | Pharmacopeia Drug Disclovery, Inc. | 2-(aminomethyl) arylamide analgesics |
| WO2004072034A1 (en) | 2003-02-17 | 2004-08-26 | F. Hoffmann-La Roche Ag | Piperidine-benzenesulfonamide derivatives |
| BRPI0407616A (pt) | 2003-03-07 | 2006-02-14 | Lilly Co Eli | composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" |
| DE10315570A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Triazolderivate |
| KR20060004967A (ko) | 2003-04-30 | 2006-01-16 | 하. 룬트벡 아크티에 셀스카브 | 방향족 옥시페닐 및 방향족 설파닐페닐 유도체 |
| JP2004359633A (ja) | 2003-06-06 | 2004-12-24 | Bayer Cropscience Ag | イソインドリノン誘導体の殺虫剤としての利用 |
| GB0314479D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Compounds |
| GB0314476D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Compounds |
| GB0314478D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Compounds |
| JP2006528186A (ja) | 2003-07-23 | 2006-12-14 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニルジヒドロベンゾイミダゾロン化合物 |
| UA85194C2 (ru) | 2003-08-11 | 2009-01-12 | Ф.Хоффманн-Ля Рош Аг | Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1 |
| NZ545613A (en) | 2003-09-09 | 2009-11-27 | Hoffmann La Roche | 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| JP4563386B2 (ja) | 2003-09-09 | 2010-10-13 | エフ．ホフマン−ラ ロシュ アーゲー | 精神病の処置のためのグリシン取り込み阻害剤としての１−（２−アミノ−ベンゾール）−ピペラジン誘導体 |
| CA2538291A1 (en) * | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
| FR2861071B1 (fr) | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique |
| FR2861070B1 (fr) | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique |
| FR2861073B1 (fr) | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
| FR2861074B1 (fr) | 2003-10-17 | 2006-04-07 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
| FR2861076B1 (fr) | 2003-10-17 | 2006-01-06 | Sanofi Synthelabo | Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique |
| JP4490434B2 (ja) | 2003-10-23 | 2010-06-23 | エフ．ホフマン−ラ ロシュ アーゲー | 神経及び神経精神疾患の処置においてＧｌｙＴ−１阻害剤として使用するためのトリアザ−スピロピペリジン誘導体 |
| US20070105902A1 (en) | 2003-11-12 | 2007-05-10 | Lindsley Craig W | 4-Phenyl piperdine sulfonyl glycine transporter inhibitors |
| GB0326840D0 (en) | 2003-11-18 | 2003-12-24 | Glaxo Group Ltd | Compounds |
| WO2005058885A2 (en) | 2003-12-18 | 2005-06-30 | Glaxo Group Limited | Piperidine derivatives and their use as glycine transporter inhibitors |
| GB0329362D0 (en) | 2003-12-18 | 2004-01-21 | Glaxo Group Ltd | Compounds |
| WO2005058317A1 (en) | 2003-12-18 | 2005-06-30 | Glaxo Group Limited | Glycine transporter-1 inhibirors |
| EP1756108A2 (en) * | 2004-04-02 | 2007-02-28 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
| US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
| DE102004030099A1 (de) | 2004-06-22 | 2006-01-12 | Grünenthal GmbH | Gesättigte und ungesättigte 3-Pyridyl-benzocycloalkylmethyl-amine als Serotonin- und/oder Noradrenalin-Reuptake-Hemmer und/oder µ-Opioidrezeptor-Modulatoren |
| PL1768967T3 (pl) | 2004-07-20 | 2009-09-30 | Symed Labs Ltd | Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne |
| WO2006025308A1 (ja) | 2004-08-31 | 2006-03-09 | Matsushita Electric Industrial Co., Ltd. | コンテンツ購入処理端末とその方法、及びプログラム |
| US20060074105A1 (en) | 2004-09-20 | 2006-04-06 | Serenex, Inc. | Substituted quinoline and quinazoline inhibitors of quinone reductase 2 |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| TWI382013B (zh) | 2004-10-14 | 2013-01-11 | Abbott Gmbh & Co Kg | 胺基氫茚多巴胺ｄ３受體拮抗劑 |
| MX2007006896A (es) | 2004-12-15 | 2007-06-26 | Hoffmann La Roche | Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer. |
| DE102005000666B3 (de) | 2005-01-04 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| SI1848694T1 (sl) | 2005-02-07 | 2010-01-29 | Hoffmann La Roche | Heterocikliäśni substituirani fenil metanoni kot inhibitorji glicinskega transporterja 1 |
| AU2006228957A1 (en) | 2005-04-01 | 2006-10-05 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2006121767A2 (en) | 2005-05-06 | 2006-11-16 | Apath, Llc | 4-aminoquinoline compounds for treating virus-related conditions |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7956050B2 (en) | 2005-07-15 | 2011-06-07 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| WO2007064914A2 (en) | 2005-12-01 | 2007-06-07 | Elan Pharmaceuticals, Inc. | 5-(arylsulfonyl)-pyrazolopiperidines |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| EP2032566A4 (en) | 2006-06-12 | 2009-07-08 | Merck Frosst Canada Ltd | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| GB0619176D0 (en) | 2006-09-29 | 2006-11-08 | Lectus Therapeutics Ltd | Ion channel modulators & uses thereof |
| WO2008038841A1 (en) | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Thiadiazolone derivative and use thereof |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| JP5130305B2 (ja) | 2007-02-15 | 2013-01-30 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしての２−アミノオキサゾリン |
| CN101687824A (zh) | 2007-04-19 | 2010-03-31 | 康塞特医药品公司 | 氘化吗啉基化合物 |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US8420683B2 (en) | 2007-06-06 | 2013-04-16 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | 5 substituted hydantoins |
| EP2178842A2 (en) | 2007-08-22 | 2010-04-28 | Abbott GmbH & Co. KG | 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| JP2010540635A (ja) | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| JP2009185008A (ja) * | 2008-02-08 | 2009-08-20 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害活性を有する化合物 |
| JP2009185010A (ja) * | 2008-02-08 | 2009-08-20 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害剤を含有する医薬 |
| EP2527328A1 (en) | 2008-04-01 | 2012-11-28 | Abbott GmbH & Co. KG | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| WO2010020548A1 (en) | 2008-08-20 | 2010-02-25 | F. Hoffmann-La Roche Ag | Glyt1 receptor antagonists |
| AU2009289846B2 (en) | 2008-09-02 | 2014-10-16 | Sanofi-Aventis | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| DE102008047162A1 (de) | 2008-09-15 | 2010-03-25 | Institut Für Solarenergieforschung Gmbh | Rückkontaktsolarzelle mit integrierter Bypass-Diode sowie Herstellungsverfahren hierfür |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| EP2246331A1 (en) | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
| WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| CN103889968A (zh) | 2011-08-05 | 2014-06-25 | 艾伯维德国有限责任两合公司 | 氨基苯并二氢吡喃、氨基苯并二氢噻喃及氨基-1,2,3,4-四氢喹啉衍生物，包含这些化合物的药用组合物，及其在治疗中的用途 |
| MX2014006004A (es) | 2011-11-18 | 2015-04-16 | Abbvie Deutschland | Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| JP2016537323A (ja) | 2013-10-17 | 2016-12-01 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミノクロマン誘導体、アミノチオクロマン誘導体およびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用 |
| AU2014336154A1 (en) | 2013-10-17 | 2016-04-28 | AbbVie Deutschland GmbH & Co. KG | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
-
2011
- 2011-08-10 US US13/206,937 patent/US8877794B2/en not_active Expired - Fee Related
- 2011-08-11 TW TW100128764A patent/TW201211031A/zh unknown
- 2011-08-12 MX MX2013001790A patent/MX2013001790A/es active IP Right Grant
- 2011-08-12 JP JP2013523638A patent/JP2013538198A/ja active Pending
- 2011-08-12 CA CA2806643A patent/CA2806643A1/en not_active Abandoned
- 2011-08-12 EP EP11748621.7A patent/EP2603487A1/en not_active Withdrawn
- 2011-08-12 CN CN201180039735XA patent/CN103237788A/zh active Pending
- 2011-08-12 WO PCT/EP2011/063971 patent/WO2012020130A1/en not_active Ceased
-
2014
- 2014-05-20 US US14/282,712 patent/US9238619B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538198A5 (enExample) | ||
| JP2013538802A5 (enExample) | ||
| RU2440330C2 (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2013538801A5 (enExample) | ||
| JP2011515398A5 (enExample) | ||
| JP2013536188A5 (enExample) | ||
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| RU2008108984A (ru) | Терапевтический агент от диабета | |
| JP2013505903A5 (enExample) | ||
| RU2409562C2 (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| RU2015143675A (ru) | Ship1 модуляторы и относящиеся к ним способы | |
| RU2006147267A (ru) | Конденсированное гетероциклическое соединение | |
| RU2008107336A (ru) | Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств | |
| RU2012123154A (ru) | Способы лечения синдрома фибромиалгии | |
| RU2011138027A (ru) | Аминотетралиновые производные, содержащие их фармацевтические композиции и их применение в терапии | |
| JP2012515166A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| RU2014122750A (ru) | Производные арилмочевины в качестве модуляторов n-формилпептидного-1 рецептора (fprl-1) | |
| RU2014145819A (ru) | Бициклическое соединение | |
| PT2114873E (pt) | Ligandos para imagiologia de inervação cardíaca | |
| RU2009128062A (ru) | Соединения агонисты и антагонисты рецептора сфингозин-1-фосфата | |
| RU2005117789A (ru) | Производные 4,5-диарилтиазола в качестве лигандов св-1 | |
| JP2008505874A5 (enExample) | ||
| RU2005117783A (ru) | 1, 5-диарилпиррол-3-карбоксамидные производные и их применение в качестве модуляторов каннабиноидных рецепторов |